KNSA - キニクサ・ファ―マシュ―ティカルズ （Kiniksa Pharmaceuticals Ltd.）

In Tuesday’s session, Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) marked $12.80 per share, up from $11.42 in the previous session. While Kiniksa Pharmaceuticals Ltd. has overperformed by 12.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KNSA rose by 0.55%, with highs and lows ranging from $15.24 to […]

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:NASDAQ:KNSA) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Rachel Frank – Head-Investor Relations Sanj K.

The following slide deck was published by Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals press release (KNSA): Q3 GAAP EPS of $3.18.Revenue of $99.13M (+719.9% Y/Y).Total revenue for the third quarter of 2022 included $33.4 million in ARCALYST…

– ARCALYST ® (rilonacept) Q3 2022 net revenue of $33.4 million – – RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard Ratio = 0.018, p<0.0001) – – KPL-404 Phase 2 data in rheumatoid arthritis expected in 1H 2024 – – Cash reserves of $200.7 million expected to fund operations into at least 2025 – – Conference call and webcast scheduled for 8:30 am ET today –

In Tuesday’s session, Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) marked $12.80 per share, up from $11.42 in the previous session. While Kiniksa Pharmaceuticals Ltd. has overperformed by 12.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KNSA rose by 0.55%, with highs and lows ranging from $15.24 to […]

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:NASDAQ:KNSA) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Rachel Frank – Head-Investor Relations Sanj K.

The following slide deck was published by Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals press release (KNSA): Q3 GAAP EPS of $3.18.Revenue of $99.13M (+719.9% Y/Y).Total revenue for the third quarter of 2022 included $33.4 million in ARCALYST…

– ARCALYST ® (rilonacept) Q3 2022 net revenue of $33.4 million – – RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard Ratio = 0.018, p<0.0001) – – KPL-404 Phase 2 data in rheumatoid arthritis expected in 1H 2024 – – Cash reserves of $200.7 million expected to fund operations into at least 2025 – – Conference call and webcast scheduled for 8:30 am ET today –

Kiniksa Pharmaceuticals (KNSA) has filed for a $400M mixed shelf offering.The filing does not necessarily indicate that a sale has begun, or will occur in the future.

Kiniksa Pharmaceuticals press release (KNSA): Q1 GAAP EPS of -$0.36 misses by $0.03.Revenue of $32.18M.

Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ: KNSA ) is projected to report earnings for its first quarter. • Great Lakes Dredge & Dock (NASDAQ: GLDD ) is likely to report quarterly earnings at $0.16 per share on revenue of $170.53 million. • Enel Chile (NYSE: ENIC ) is expected to report quarterly earnings at $82.88 per share on revenue of $994.35 million. • Paramount Global (NASDAQ: PARAA ) is likely to report quarterly earnings at $0.52 per share on revenue of $7.38 billion. • Triton International (NYSE: TRTN ) is likely to report quarterly earnings at $2.63 per share on revenue of $419.07 million. • Colliers Intl Gr (NASDAQ: CIGI ) is likely to report quarterly earnings at $1.59 per share on revenue of $1.14 billion. • Comstock Mining (AMEX: LODE ) is projected to report quarterly loss at $0.03 per share on revenue of $380.00 thousand. • GEO Group (NYSE: GEO ) is expected to report quarterly earnings at $0.22 per share on revenue of $551.47 million. • Kopin (NASDAQ: KOPN ) is expected to report quarterly loss at $0.

HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30 a.m. Eastern Time to report its first quarter 2022 financial results and corporate activities.

ATLANTA , March 3, 2022 /PRNewswire-PRWeb/ -- Wayne H. Elowe , co-chair of the Life Sciences and Medical Technology Group at global law firm Greenberg Traurig, LLP and co-chair of the firm''s Atlanta Corporate Practice, led the Greenberg Traurig team representing Huadong Medicine Co., Ltd., one of the leading pharmaceutical companies in China with a focus on oncology and Antibody-drug Conjugates research, development, and commercialization, on two large licensing deals, both of which closed in February 2022 . These deals mark the continuation of a longstanding relationship between Huadong Medicine and Greenberg Traurig Shareholders Elowe and Dawn (Dan) Zhang ( Shanghai ) who have represented Huadong in numerous transactions. In the first deal, Elowe advised Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly owned subsidiary of Huadong Medicine , in a strategic collaboration with Kiniksa Pharmaceuticals, Ltd., a U.S. biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, to develop …